Tandem Diabetes Care COO granted RSUs
Kyrillos Jean-Claude reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kyrillos Jean-Claude reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive vice president and chief operating officer Jean-Claude Kyrillos received a grant of 29,136 restricted stock units (RSUs). Each RSU represents a contingent right to one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.
One-third of these RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to plan terms. Following this grant, Kyrillos directly holds 29,136 RSUs linked to common stock.
Insider Trade Summary
Grant/Award: 29,136 shares
Grant/Award
1 txn
Insider
Kyrillos Jean-Claude
Role
EVP & Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 29,136 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Unit — 29,136 contracts (Direct)
Footnotes (2)
- F1. Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
- F2. One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter subject to the terms of the 2023 Plan.
Key Figures
RSUs granted: 29,136 units
RSUs underlying shares: 29,136 shares
Post-grant RSU holdings: 29,136 units
+2 more
5 metrics
RSUs granted
29,136 units
Restricted stock units granted to EVP & COO on May 29, 2026
RSUs underlying shares
29,136 shares
Common stock underlying the RSU grant
Post-grant RSU holdings
29,136 units
Total RSUs held directly following the reported transaction
Initial vesting date
May 29, 2027
One-third of RSUs vest on this date under the 2023 Plan
Remaining vesting pattern
8 quarterly installments
Balance of RSUs vest in eight equal quarterly installments thereafter
Key Terms
Restricted Stock Unit, contingent right, 2023 Long-Term Incentive Plan, vest
4 terms
Restricted Stock Unit financial
"Each restricted stock unit (RSU) represents a contingent right to receive either one share..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
contingent right financial
"Each restricted stock unit (RSU) represents a contingent right to receive either one share..."
2023 Long-Term Incentive Plan financial
"in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan..."
vest financial
"One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Tandem Diabetes Care (TNDM) report for Jean-Claude Kyrillos?
Tandem Diabetes Care reported that EVP and COO Jean-Claude Kyrillos received a grant of 29,136 restricted stock units. These RSUs were awarded as part of the company’s 2023 Long-Term Incentive Plan and are settled in stock or cash at the company’s discretion.
How many restricted stock units did TNDM grant to its COO?
The COO of Tandem Diabetes Care, Jean-Claude Kyrillos, was granted 29,136 restricted stock units. Each unit is tied to one share of common stock or cash and is subject to a multi-year vesting schedule under the 2023 Long-Term Incentive Plan.
What is the vesting schedule for Jean-Claude Kyrillos’ 29,136 RSUs at Tandem Diabetes Care?
One-third of the 29,136 RSUs will vest on May 29, 2027. The remaining two-thirds will then vest in eight equal quarterly installments on the 15th of the month, all subject to the terms of Tandem Diabetes Care’s 2023 Long-Term Incentive Plan.
What does each RSU granted to TNDM’s COO represent?
Each restricted stock unit granted to TNDM’s COO represents a contingent right to receive either one share of Tandem Diabetes Care common stock or cash. Settlement form is at the company’s discretion and governed by the 2023 Long-Term Incentive Plan and related agreements.
How many RSUs does Jean-Claude Kyrillos hold after this Form 4 transaction?
After this transaction, Jean-Claude Kyrillos directly holds 29,136 restricted stock units. These RSUs are derivative securities linked to Tandem Diabetes Care common stock and will convert into shares or cash as they vest under the plan’s terms over time.
Under which plan were the RSUs for Tandem Diabetes Care’s COO granted?
The RSUs were granted under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended. This plan governs key terms such as settlement in stock or cash, vesting schedule, and other conditions tied to executive equity compensation awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates